Pathogenesis and therapy of psoriasis and psoriatic arthritis

Matushevskaia E.V.; Konovalova M.V.; Vladimirova E.V.; Svirshchevskaia E.V.

doi:https://doi.org/10.17116/klinderma201918051634

Close metadata

Recommended articles:

Black Acanthosis: Diagnosis and Treatment Issues. Russian Journal of Clinical Dermatology and Venereology. 2024;(6):709-712

Infectious factors in atopic dermatitis, pharmaceutical possibilities (systematic literature review). Russian Journal of Clinical Dermatology and Venereology. 2025;(1):7-15

Psoriasis: analysis of comorbid pathology. Russian Journal of Clinical Dermatology and Venereology. 2025;(1):16-21

Epidemiology of M. genitalium infection. What is known?. Russian Journal of Clinical Dermatology and Venereology. 2025;(2):143-152

Modern view on the etiology of gallstone disease in children. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):59-68

Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90

The association of NOS1AP gene polymorphisms with the duration of the QT interval in patients with schizophrenia receiving antipsychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104

Liver pathology in COVID-19. Russian Journal of Archive of Pathology. 2025;(1):53-59

A modern perspective on the pathogenesis of proliferative diabetic retinopathy. Russian Annals of Ophthalmology. 2025;(1):92-98

Characteristics, treatment features and in-hospital mortality of patients with myocardial infarction over 75 years old in Russia according to the REGION-IM registry. Russian Cardiology Bulletin. 2025;(1):22-38

Abstract:

Psoriasis is a systemic chronic genetically mediated autoimmune disease, in the pathogenesis of which the activation of T-helpers 17, producing interleukin-17 (IL), plays a central role. Psoriasis occurs early (up to 40 years) and is associated with the presence of the allele of the main histocompatibility complex HLA-Cw6, which is able to represent the cathelycidine LL-37 immune T-cells, which leads to early activation of adaptive immunity. Pustular psoriasis occurs after 50 years of age and is mediated by a defective signaling pathway inhibitor of tissue cytokine IL-36, which results in activation of the congenital immunity system with the subsequent involvement of an adaptive link. Pustular formation is associated with the activation of keratinocytes by inflammas and pyroptosis. The review presents the data of foreign and domestic studies on the study of pathogenesis and treatment of psoriasis of various severity. The main directions of psoriasis treatment based on international and Russian clinical recommendations have been singled out, as well as the place of topical combined drugs in psoriasis therapy. The efficacy and safety of application of topical preparation betamethasone + salicylic acid (ointment) in the treatment of mild and medium severity forms of psoriasis in the wide practice of dermatovenerologist is shown.

Keywords:

psoriasis

pathogenesis

therapy

topical GCS

salicylic acid

combined therapy

betamethasone + salicylic acid ointment

Authors:

Matushevskaia E.V.

FGOU Institut povysheniia kvalifikatsii Federal'nogo mediko-biologicheskogo agentstva RF, Moskva

Konovalova M.V.

Immunology Department, Shemyakin—Ovchinnikov Institute of bioorganic chemistry RAS, Moscow, Russia

Vladimirova E.V.

Institute of Advanced Training, Federal Medico-Biological Agency of the Russian Federation, Moscow

Svirshchevskaia E.V.

Institut bioorganicheskoĭ khimii im. M.M. Shemiakina i Iu.A. Ovchinnikova RAN, Moskva, 117997, Rossiĭskaia Federatsiia

Close metadata

References:

Rossiiskoe obshchestvo dermatovenerologov i kosmetologov, Federal’nye klinicheskie rekomendatsii po vedeniyu bol’nykh psoriazom. M., 2015. Accessed September 5, 2019. (In Russ.) https://www.ismos.ru/guidelines/doc/psoriaz.pdf
Kurd SK, Gelfand JM.The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003—2004, J. Am. Acad. Dermatol. 2009;60:218-224. https://doi.org/10.1016/j.jaad.2008.09.022
Augustin M, Reich K, Glaeske G, et al. Co-morbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in Germany. Acta Derm. Venereol. 2010;90:147-151. https://doi.org/10.2340/00015555-0770
Kubanova AA, Kubanov AA, Melekhina LE, Bogdanova EV. Dermatovenereologic healthcare delivery in Russian Federation. Incidence of sexually transmitted infections and skin disorders, 2013—2015. Vestn dermatol i venerol. 2016;3:12-28. Àccessed September 5, 2019. (In Russ.) https://www.vestnikdv.ru/jour/article/view/235/236
Parisi R, et al. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. J. Invest. Dermatol. 2013;133:377-385. https://doi.org/10.1038/JID.2012.339
Rendon A, Schkel K. Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci. 2019;20:1475. https://doi.org/10.3390/ijms20061475
Feldman SR. Disease Burden and Treatment Adherence in Psoriasis Patients. Cutis. 2013;92:258-263. Àccessed September 5, 2019. https://mdedge-files-live.s3.us-east-2.amazonaws.com/files/s3fs-public/Document/September-2017/CT092050258.pdf
Augustin M, et al.Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany. Dermatology. 2008;216:366-372. https://doi.org/10.1159/000119415
Yeung H, et al. Psoriasis severity and the prevalence of major medical co-morbidities: a population-based study. JAMA Dermatol. 2013;149:1173. https://doi.org/10.1001/JAMADERMATOL.2013.5015
Bakulev AL, Fitileva TV, Novoderezhkina EA, et al. Psoriasis: clinical and epidemiological features and therapy issues. Vestnik dermatologii i venerologii. 2018;94:67-76. Àccessed September 5, 2019. (In Russ.) https://www.vestnikdv.ru/jour/article/view/407/401
Gladman D, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome, Ann. Rheum. Dis. 2005; 64:ii14.d. https://doi.org/10.1136/ARD.2004.032482
Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J. Am. Acad. Dermatol. 2008;58:826-850. https://doi.org/10.1016/j.jaad.2008.02.039
Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J. Am. Acad. Dermatol. 2008;58:851-864. https://doi.org/10.1016/J.JAAD.2008.02.040
Boehncke W-H, Boehncke S, Schön MP. Managing comorbid disease in patients with psoriasis. BMJ. 2010;340:b5666. https://doi.org/10.1136/BMJ.B5666
Mrowietz U, et al. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch. Dermatol. Res. 2006;298:309-319. https://doi.org/10.1007/s00403-006-0707-8
Bernstein CN, et al. The Clustering of Other Chronic Inflammatory Diseases in Inflammatory Bowel Disease: A Population-Based Study. Gastroenterology. 2005;129:827-836. https://doi.org/10.1053/J.GASTRO.2005.06.021
Liang Y, et al. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr. Opin. Immunol. 2017;49:1-8. https://doi.org/10.1016/j.coi.2017.07.007
Basavaraj KH, et al. The role of drugs in the induction and/or exacerbation of psoriasis. Int. J. Dermatol. 2010;49:1351-1361. https://doi.org/10.1111/j.1365-4632.2010.04570.x
Perera GK, et al. Psoriasis, Annu. Rev. Pathol. Mech. Dis. 2012;7:385-422. https://doi.org/10.1146/annurev-pathol-011811-132448
Zeng J, et al. Critical role of environmental factors in the pathogenesis of psoriasis. J. Dermatol. 2017;44:863-872. https://doi.org/10.1111/1346-8138.13806
Elder JT. Expanded Genome-Wide Association Study Meta-Analysis of Psoriasis Expands the Catalog of Common Psoriasis-Associated Variants. J. Investig. Dermatology Symp. Proc. 2018;19:77-78. https://doi.org/10.1016/j.jisp.2018.09.005
Gudjonsson JE, et al. Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br. J. Dermatol. 2003;148:233-235. https://doi.org/10.1046/j.1365-2133.2003.05115.x
Capon F. The Genetic Basis of Psoriasis. Int. J. Mol. Sci. 2017;18:2526. https://doi.org/10.3390/ijms18122526
Allen MH, Ameen H, Veal C, et al. The Major Psoriasis Susceptibility Locus PSORS1 Is not a Risk Factor for Late-Onset Psoriasis. J. Invest. Dermatol. 2005;124:103-106. https://doi.org/10.1111/J.0022-202X.2004.23511.X
Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36—Receptor Antagonist Deficiency and Generalized Pustular Psoriasis. N. Engl. J. Med. 2011;365:620-628. https://doi.org/10.1056/NEJMoa1013068
Johnston A, Xing X, Guzman AM, et al. IL-1F5, F6, F8, and F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J. Immunol. 2011;186:2613. https://doi.org/10.4049/JIMMUNOL.1003162
Körber A, Mössner R, Renner R, et al. Mutations in IL36RN in Patients with Generalized Pustular Psoriasis. J. Invest. Dermatol. 2013;133:2634-2637. https://doi.org/10.1038/JID.2013.214
Eppinga H, Sperna Weiland CJ, Thio HB, et al. Similar Depletion of Protective Faecalibacterium prausnitzii in Psoriasis and Inflammatory Bowel Disease, but not in Hidradenitis Suppurativa. J. Crohn’s Colitis. 2016;10:1067-1075. https://doi.org/10.1093/ecco-jcc/jjw070
D’Erme AM, Wilsmann-Theis D, Wagenpfeil J, et al. IL-36γ (IL-1F9) Is a Biomarker for Psoriasis Skin Lesions. J. Invest. Dermatol. 2015;135:1025-1032. https://doi.org/10.1038/JID.2014.532
Teng MWL, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat. Med. 2015;21:719-729. https://doi.org/10.1038/nm.3895
Shimauchi T, Hirakawa S, Suzuki T, et al. Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis. J. Dermatol. 2013;40:n/a-n/a. https://doi.org/10.1111/1346-8138.12248
Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J. Allergy Clin. Immunol. 2015;135:324-336. https://doi.org/10.1016/J.JACI.2014.11.015
Harden JL, et al. Humanized anti—IFN-γ (HuZAF) in the treatment of psoriasis. J. Allergy Clin. Immunol. 2015;135:553-556.e3. https://doi.org/10.1016/J.JACI.2014.05.046
Arakawa A, et al. Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status. JAMA Dermatology. 2016;152:825. https://doi.org/10.1001/jamadermatol.2016.0751
Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: A comprehensive review. J. Autoimmun. 2015;64:66-73. https://doi.org/10.1016/j.jaut.2015.07.008
Morizane S, Gallo RL. Antimicrobial peptides in the pathogenesis of psoriasis. J. Dermatol. 2012;39:225-30. https://doi.org/10.1111/j.1346-8138.2011.01483.x
Dombrowski Y, Schauber J. Cathelicidin LL-37: a defense molecule with a potential role in psoriasis pathogenesis. Exp. Dermatol. 2012;21:327-330. https://doi.org/10.1111/j.1600-0625.2012.01459.x
Li N, Yamasaki K, Saito R, et al. Alarmin Function of Cathelicidin Antimicrobial Peptide LL37 through IL-36γ Induction in Human Epidermal Keratinocytes. J. Immunol. 2014;193:5140-5148. https://doi.org/10.4049/jimmunol.1302574
Morizane S, Yamasaki K, Mühleisen B, et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J. Invest. Dermatol. 2012;132:135-43. https://doi.org/10.1038/jid.2011.259
Van der Fits L, Mourits S, Voerman JSA, et al. Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis. J. Immunol. 2009;182:5836-5845. https://doi.org/10.4049/JIMMUNOL.0802999
Boehncke W-H, Schön MP. Animal models of psoriasis. Clin. Dermatol. 2007;25:596-605. https://doi.org/10.1016/J.CLINDERMATOL.2007.08.014
Veal CD, Capon F, Allen MH, et al. Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. Am. J. Hum. Genet. 2002;71:554-64. https://doi.org/10.1086/342289
Capon F, Munro M, et al. Searching for the Major Histocompatibility Complex Psoriasis Susceptibility Gene. J. Invest. Dermatol. 2002;118:745-751. https://doi.org/10.1046/J.1523-1747.2002.01749.X
Su F, Xia Y, Huang M, et al. Expression of NLPR3 in Psoriasis Is Associated with Enhancement of Interleukin-1β and Caspase-1. Med. Sci. Monit. 2018;24:7909-7913. https://doi.org/10.12659/MSM.911347
Hiruma J, Harada K, Motoyama A, et al. Key component of inflammasome, NLRC4, was identified in the lesional epidermis of psoriatic patients. J. Dermatol. 2018;45:971-977. https://doi.org/10.1111/1346-8138.14478
Dombrowski Y, et al. Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions. Sci. Transl. Med. 2011;3:82ra38. https://doi.org/10.1126/scitranslmed.3002001
Ekman A-K, Verma D, Fredrikson M, et al. Genetic variations of NLRP1: susceptibility in psoriasis. Br. J. Dermatol. 2014;171:1517-1520. https://doi.org/10.1111/bjd.13178
Benhadou F, et al. Psoriasis and Microbiota: A Systematic Review. Dis. Basel, Switzerland. 2018;6. https://doi.org/10.3390/diseases6020047
Fahlen A, et al. Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skin. Arch. Dermatol. Res. 2012;304:15-22. https://doi.org/10.1007/s00403-011-1189-x
Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin. Dermatol. 2007;25:606-615. https://doi.org/10.1016/J.CLINDERMATOL.2007.08.015
Mcfadden J, et al. Cross-reactivity between streptococcal M surface antigen and human skin. Br. J. Dermatol. 1991;125:443—447. https://doi.org/10.1111/j.1365-2133.1991.tb14769.x
Valdimarsson H, et al. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol. Today. 1995;16:145-149. https://doi.org/10.1016/0167-5699(95)80132-4
Alekseyenko AV, Perez-Perez GI, De Souza A, et al. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome. 2013;1:31. https://doi.org/10.1186/2049-2618-1-31
Fry L, Baker BS, Powles AV, et al. Is chronic plaque psoriasis triggered by microbiota in the skin? Br. J. Dermatol. 2013;169:7-52. https://doi.org/10.1111/bjd.12322
Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015. Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016;68:n/a-n/a. https://doi.org/10.1002/art.39573
Kreuter A, Sommer A, Hyun J, et al. 1% Pimecrolimus, 0.005% calcipotriol, and0.1% betamethasone in the treatment of intertriginouspsoriasis: a double-blind, randomized controlled study. Arch Dermatol. 2006;142:1138-1143.
Callen J. Comparison of safety and efficacy of fluticasone propionate cream, 0.05%, and betamethasone valerate cream, 0.1%, in the treatment of moderate-to-severe psoriasis. Cutis. 1996;57:45-50. Àccessed September 5, 2019. http://www.ncbi.nlm.nih.gov/pubmed/8646870
Roberts DT. Comparison of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of psoriasis. Cutis. 1996;57:27-31. https://doi.org/10.1016/j.jaad.2011.01.022
Singh S, et al. Topical 0.05% betamethasone dipropionate: efficacy in psoriasis with once a day vs. twice a day application. Br. J. Dermatol. 1995;133:497-498. https://doi.org/10.1111/j.1365-2133.1995.tb02693.x
Lebwohl M. The role of salicylic acid in the treatment of psoriasis. Int. J. Dermatol. 1999;38:16-24. https://doi.org/10.1046/j.1365-4362.1999.00500.x
Jacobi A, Mayer A, Augustin M. Keratolytics and Emollients and Their Role in the Therapy of Psoriasis: a Systematic Review. Dermatol. Ther. (Heidelb). 2015;5:1-18. https://doi.org/10.1007/s13555-015-0068-3
Strober BE, van der Walt JM, Armstrong AW, et al. Clinical Goals and Barriers to Effective Psoriasis Care. Dermatol. Ther. (Heidelb). 2019;9:5-18. https://doi.org/10.1007/s13555-018-0279-5
Keating GM. Apremilast: A Review in Psoriasis and Psoriatic Arthritis. Drugs. 2017;77(4):459-472. https://doi.org/10.1007/s40265-017-0709-1
Srivastava A, Ståhle M, Pivarcsi A, et al. Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes. Acta Derm Venereol. 2018;98(8):772-775. https://doi.org/10.2340/00015555-2960
Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann. Rheum. Dis. 2016;75:499-510. https://doi.org/10.1136/annrheumdis-2015-208337
Fraser AD, van Kuijk AW, Westhovens R, et al. A randomized, double blind, placebo controlled, multicenter trial of combination therapy withmethotrexate plus cyclosporin in patients with active psori-atic arthritis. Ann Rheum Dis. 2005;64:859-864.